AstraZeneca Invests $2 Billion in Summit Therapeutics to Test Cancer Drug Combinations

UK pharmaceutical company AstraZeneca has agreed to invest $2 billion in US biotech Summit Therapeutics, alongside a clinical partnership to test cancer drug combinations involving Summit's bispecific antibody ivonescimab. The deal represents one of the larger strategic investments in oncology biotech this year.

Ivonescimab is a bispecific antibody that simultaneously targets PD-1 and VEGF — two pathways that tumours exploit to evade the immune system and build blood supply. The dual mechanism is designed to improve on existing checkpoint inhibitors that target PD-1 alone, potentially offering stronger anti-tumour activity in certain cancer types.

The partnership will explore combinations of ivonescimab with AstraZeneca's existing oncology portfolio, which includes blockbuster drugs like the PD-L1 inhibitor Imfinzi and the PARP inhibitor Lynparza. Combination therapies have become the dominant strategy in oncology drug development, as single-agent responses often prove insufficient for durable remission.

The $2 billion price tag reflects both the scale of AstraZeneca's oncology ambitions and the competitive dynamics of the bispecific antibody space, where several companies are racing to prove that dual-targeting designs outperform established monotherapies. Whether ivonescimab's clinical data will justify the investment depends on results from trials that are yet to read out.